Dalteparin Sodium Injection
a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant.
•Dalteparin Sodium is used to treat blood clots (venous thromboembolism) and to prevent their recurrence. Venous thromboembolism is a condition where blood clots develop in the legs (deep vein thrombosis) or the lungs (pulmonary embolism), e.g. after surgery, prolonged bed-rest or in patients with certain types of cancer.
•Dalteparin Sodium is also used to treat a condition known as unstable coronary artery disease. In coronary artery disease the coronary arteries (blood vessels to the heart) are furred up and narrowed by patches of fatty deposits.
•Unstable coronary artery disease means that a furred up bit of the artery has ruptured and a clot has formed on it, reducing the flow of blood to the heart. Patients with this condition may be more likely to go on to have a heart attack without treatment with blood thinning drugs such as Dalteparin Sodium.
Store at 20-25℃, excursions permitted to 15-30℃.
Dalteparin sodium has the most ideal molecular weight distribution, and has both anticoagulant efficacy and safety. The molecular weight distribution of dalteparin sodium is the most concentrated, the antithrombotic activity is the strongest, the low molecular fragments are less, the drug accumulation is less, the polymer fragments are less, the binding rate with platelets is low, the incidence of HIT is low, and the bleeding risk is small.
It is safer for special groups：
1. Dapaparin is the only low-molecular-weight heparin approved by the US FDA for safe use in the elderly.
2. Dalteparin sodium is the only low-molecular-weight heparin that has no significant accumulation in patients with renal impairment.